CTLT Logo

Catalent, Inc. (CTLT) 

NYSE
Market Cap
$11.45B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
628 of 963
Rank in Industry
36 of 59

Largest Insider Buys in Sector

CTLT Stock Price History Chart

CTLT Stock Performance

About Catalent, Inc.

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Insider Activity of Catalent, Inc.

Over the last 12 months, insiders at Catalent, Inc. have bought $0 and sold $1.57M worth of Catalent, Inc. stock.

On average, over the past 5 years, insiders at Catalent, Inc. have bought $671,930 and sold $327.18M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,000 shares for transaction amount of $49,980 was made by Ryan Michelle R (director) on 2023‑08‑31.

List of Insider Buy and Sell Transactions, Catalent, Inc.

2024-11-11Saledirector
2,800
0.0015%
$59.70$167,160+3.08%
2024-10-18SaleSVP, General Counsel, CCO
320
0.0002%
$59.97$19,190-0.18%
2024-09-26SaleGroup President, Biologics
1,994
0.0011%
$59.97$119,580+0.53%
2024-08-02SaleGroup Pres. Pharma & Consumer
1,169
0.0006%
$59.55$69,614+0.96%
2024-08-02SaleSVP, Quality & Reg. Affairs
666
0.0004%
$59.55$39,660+0.96%
2024-08-02SaleSVP, Chief HR Officer
3,859
0.0021%
$59.67$230,267+0.96%
2024-08-02SalePres. BioProduct Delivery, CoS
662
0.0004%
$59.56$39,429+0.96%
2024-08-02SaleSVP, General Counsel, CCO
608
0.0003%
$59.58$36,225+0.96%
2024-07-29SalePresident & CEO
9,088
0.005%
$58.76$534,011+1.92%
2024-07-29SaleGroup Pres. Pharma & Consumer
349
0.0002%
$58.70$20,486+1.92%
2024-07-29SaleSVP, Quality & Reg. Affairs
283
0.0002%
$58.69$16,609+1.92%
2024-07-29SalePres. BioProduct Delivery, CoS
206
0.0001%
$58.67$12,086+1.92%
2024-07-08SaleSVP, Chief Financial Officer
2,993
0.0017%
$56.74$169,8230.00%
2024-06-04SalePres. BioProduct Delivery, CoS
1,401
0.0008%
$54.26$76,023+8.65%
2024-03-15SaleSVP, Quality & Reg. Affairs
387
0.0002%
$56.20$21,749+4.21%
2023-08-31Purchasedirector
1,000
0.0006%
$49.98$49,980+9.95%
2023-08-30PurchaseExecutive Chair
21,000
0.012%
$50.24$1.06M+12.17%
2023-08-24SaleGroup Pres. Pharma & Consumer
396
0.0002%
$44.49$17,618+22.22%
2023-08-24SalePresident & CEO
2,071
0.0011%
$44.54$92,245+22.22%
2023-08-24SaleEVP & Chief Admin Officer
817
0.0004%
$44.65$36,479+22.22%

Insider Historical Profitability

17.86%
Maselli AlessandroPresident & CEO
177521
0.0978%
$63.1009
Gennadios AristipposGroup Pres. Pharma & Consumer
113724
0.0627%
$63.10014
Gunther ScottSVP, Quality & Reg. Affairs
39635
0.0218%
$63.10014
Evoli LisaSVP, Chief HR Officer
39366
0.0217%
$63.1001
McErlane DavidGroup President, Biologics
36304
0.02%
$63.1001
Masanovich MattiSVP, Chief Financial Officer
33871
0.0187%
$63.1001
Hopson RickyPres. BioProduct Delivery, CoS
29974
0.0165%
$63.10012
Ferraro Joseph AnthonySVP, General Counsel, CCO
23967
0.0132%
$63.1002
Ryan Michelle Rdirector
10835
0.006%
$63.1011
Zippelius Peterdirector
4330462
2.3858%
$63.1003
Chiminski John RExecutive Chair
229888
0.1267%
$63.10019
WALSH MATTHEW MSee Remarks
93712
0.0516%
$63.1006
Fasman Steven LEVP & Chief Admin Officer
73789
0.0407%
$63.10015
Arnold JonathanSVP, CCO & Div. Head BioP Del.
57399
0.0316%
$63.10010
Joseph WettenySVP & Chief Financial Officer
49823
0.0274%
$63.1003
MOREL DONALD E JRdirector
46958
0.0259%
$63.1030+15.26%
Miyamoto LanceSVP, Human Resources
46799
0.0258%
$63.1003
BUZY PETER LPresident, Gene Therapy
44500
0.0245%
$63.1010+17.25%
Leonard StephenSee Remarks
44531
0.0245%
$63.1002
Littlejohns BarryPresident, Biologics & SDD
37718
0.0208%
$63.1002
Downie WilliamSVP, Global Sales & Marketing
34926
0.0192%
$63.1005
GREISCH JOHN JExecutive Chair
34000
0.0187%
$63.1020+20.08%
Flynn KarenChief Commercial Officer
33223
0.0183%
$63.1003
Pravda RicardoChief Transformation Officer
30224
0.0167%
$63.10010
Grippo Michael JSVP, Strategy & Corp. Dev.
24449
0.0135%
$63.10015
Kurt NielsenSee Remarks
23676
0.013%
$63.1001
Houlton ScottSee Remarks
23146
0.0128%
$63.1003
Johnson SharonSee Remarks
22520
0.0124%
$63.1003
Castellano Thomas PSVP, Chief Financial Officer
20099
0.0111%
$63.1005
Dolan ChristineSVP - Product Development
19449
0.0107%
$63.1002
Schmidt Kay ASVP, Enterprise Functions
17388
0.0096%
$63.1008
Roehrhoff Uwedirector
16489
0.0091%
$63.1010+6.41%
Boerman ManjaPres. BioModalities Division
14414
0.0079%
$63.1003
Hunt PatriciaPres. Consumer Health Div
11289
0.0062%
$63.1003
Lickfold CharlesSVP, CIO
11339
0.0062%
$63.1002
Carletti LorenzoSVP Global Ops Ph & Cons Hlth
8746
0.0048%
$63.1004
Hawkeswood Thomas WPres. Pharma Prod Delivery Div
7533
0.0042%
$63.1004
Riley Michael A.Pres. Bio Product Delivery Div
6592
0.0036%
$63.1002
Gargiulo MarioSVP, Ops, Biologics Europe
5676
0.0031%
$63.1004
Whitlow Ricci SPresident, CSS
2923
0.0016%
$63.1003
LUCIER GREGORY Tdirector
0
0%
$63.1032+23.73%
Blackstone Management Associates V L.L.C.10 percent owner
0
0%
$63.1005

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$1.15B11.2820.41M+1.08%+$12.34M0.02
BlackRock$857.85M8.415.2M-6.05%-$55.29M0.02
Capital World Investors$729.58M7.1412.92M-32.26%-$347.48M0.12
Nomura Holdings$635.69M6.2211.26M-1.97%-$12.77M5.55
Janus Henderson$539.7M5.289.56M-27.84%-$208.22M0.27
State Street$418.93M4.17.42M-0.47%-$1.96M0.02
Veritas Asset Management LLP$340.13M3.336.03M-6.84%-$24.98M2.47
T. Rowe Price$290.39M2.845.14M-38.96%-$185.33M0.04
Barclays$269.04M2.634.77M+27.99%+$58.84M0.12
Geode Capital Management$235.05M2.314.17M+3.41%+$7.74M0.02
T Rowe Price Investment Management Inc$231.37M2.274.1M-63.44%-$401.4M0.14
Elliott Investment Management L P$225.8M2.214M0%+$02.37
Leonard Green & Partners$218.24M2.143.87M-10.97%-$26.89M3.97
Hudson Bay Capital Management LP$184.22M1.83.26M+581.28%+$157.18M1.23
Cadian Capital Management LP$182.1M1.783.23M-46.81%-$160.24M6.48
Invesco$177.37M1.743.14M-17.77%-$38.34M0.04
Alpine Associates Management Inc$112.08M1.11.99MNew+$112.08M0.29
Millennium Management LLC$102.75M1.011.82M+5,389.41%+$100.88M0.07
Marshall Wace$96.33M0.941.71M+65.72%+$38.2M0.1
BNY Mellon$94.81M0.931.68M-3.13%-$3.06M0.02
Northern Trust$92.91M0.911.65M-19.98%-$23.2M0.02
Charles Schwab$91.01M0.891.61M+3.31%+$2.92M0.02
Capital International Investors$82.86M0.811.47M-50.98%-$86.17M0.02
Morgan Stanley$80.8M0.791.43M-14.09%-$13.25M0.01
Deutsche Bank$74.43M0.731.32M+47.58%+$23.99M0.03
JPMorgan Chase$66.93M0.661.19M+38.25%+$18.52M0.01
Dimensional Fund Advisors$62.89M0.621.11M-32.04%-$29.65M0.02
Legal & General$62.42M0.611.11M-6.41%-$4.28M0.01
UBS$59.21M0.581.05M+44.37%+$18.2M0.02
Schroder Investment Management Group$57.82M0.571.02M-23.06%-$17.33M0.07
Magnetar Capital$56.43M0.55999,628New+$56.43M1.65
Westchester Capital Funds$55.42M0.54981,725New+$55.42M0.52
AllianceBernstein$54.48M0.53965,060+364.78%+$42.76M0.02
Balyasny Asset Management Llc$52.18M0.51924,417New+$52.18M0.14
Fil Ltd$50.97M0.5903,000New+$50.97M0.05
Nuveen$47.27M0.46837,435-4.34%-$2.14M0.01
Assenagon Asset Management S.A.$47.14M0.46835,029+90.04%+$22.33M0.12
Castle Hook Partners Lp$46.93M0.46831,437-19.03%-$11.03M1.7
Adage Capital Partners Gp L L C$46.7M0.46827,300+202.96%+$31.29M0.09
Goldman Sachs$45.34M0.44803,101-10.56%-$5.35M0.01
Citigroup$45.17M0.44800,144-24.12%-$14.36M0.03
TSW (Thompson, Siegel & Walmsley LLC)$42.73M0.42756,866-18.11%-$9.45M0.66
Woodline Partners LP$40.34M0.4714,585New+$40.34M0.34
The Manufacturers Life Insurance Company$37.35M0.37661,678-14.19%-$6.18M0.03
Redmile Group$35.7M0.35632,464-42.53%-$26.42M0.36
Bank of America$33.26M0.33589,269+3.83%+$1.23M<0.01
HSBC$32.75M0.32580,253+58.44%+$12.08M0.02
Quinn Opportunity Partners Llc$32.12M0.31568,928New+$32.12M2.45
Ubs Asset Management Americas Inc$31.56M0.31559,135-2.01%-$647,650.830.01
Water Island Capital Llc$30.76M0.3544,860New+$30.76M5.62
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.